Triazolyl macrocyclic hepatitis C serine protease inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 2010
Grant Date -
Feb 19, 2009
app pub date -
Aug 8, 2007
filing date -
Aug 11, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully